NASDAQ:AGLE - Aeglea Bio Therapeutics Stock Price, Forecast & News

Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) posted its quarterly earnings data on Monday, February, 24th. The biotechnology company reported ($0.65) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.67) by $0.02. View Aeglea Bio Therapeutics' Earnings History.

Aeglea Bio Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Aeglea Bio Therapeutics.

3 brokerages have issued 1 year price targets for Aeglea Bio Therapeutics' shares. Their forecasts range from $14.00 to $24.00. On average, they expect Aeglea Bio Therapeutics' stock price to reach $17.33 in the next year. This suggests a possible upside of 135.2% from the stock's current price. View Analyst Price Targets for Aeglea Bio Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aeglea Bio Therapeutics.

Media stories about AGLE stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aeglea Bio Therapeutics earned a news sentiment score of 2.4 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Aeglea Bio Therapeutics.

Aeglea Bio Therapeutics saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 242,800 shares, an increase of 16.1% from the January 30th total of 209,200 shares. Based on an average daily volume of 58,900 shares, the days-to-cover ratio is presently 4.1 days. Approximately 1.0% of the shares of the company are short sold. View Aeglea Bio Therapeutics' Current Options Chain.

Some companies that are related to Aeglea Bio Therapeutics include Rhythm Pharmaceuticals (RYTM), Stoke Therapeutics (STOK), Radius Health (RDUS), Amphastar Pharmaceuticals (AMPH), Dova Pharmaceuticals (DOVA), Collegium Pharmaceutical (COLL), CannTrust (CNTTF), Arcus Biosciences (RCUS), Aprea Therapeutics (APRE), DiaMedica Therapeutics (DMCAF), Homology Medicines (FIXX), ImmunoGen (IMGN), Frequency Therapeutics (FREQ), Eagle Pharmaceuticals (EGRX) and ANI Pharmaceuticals (ANIP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea Bio Therapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Corbus Pharmaceuticals (CRBP), Kura Oncology (KURA), Abeona Therapeutics (ABEO), AcelRx Pharmaceuticals (ACRX), Aduro BioTech (ADRO), Amicus Therapeutics (FOLD) and Iovance Biotherapeutics (IOVA).

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

Aeglea Bio Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Marshall Wace LLP (2.88%), Renaissance Technologies LLC (1.99%), State Street Corp (1.60%), Goldman Sachs Group Inc. (1.53%), University of Texas Texas AM Investment Managment Co. (1.11%) and Comprehensive Portfolio Management LLC (0.84%). Company insiders that own Aeglea Bio Therapeutics stock include Aaron Schuchart, Anthony G Quinn and Bioventures Ltd Novartis. View Institutional Ownership Trends for Aeglea Bio Therapeutics.

AGLE stock was sold by a variety of institutional investors in the last quarter, including Comprehensive Portfolio Management LLC, New York State Common Retirement Fund, Oxford Asset Management LLP, UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Aeglea Bio Therapeutics.

AGLE stock was bought by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co., P.A.W. Capital Corp, California Public Employees Retirement System, State Street Corp, Marshall Wace LLP, Renaissance Technologies LLC, Barclays PLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Aeglea Bio Therapeutics.

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGLE stock can currently be purchased for approximately $7.37.

Aeglea Bio Therapeutics has a market capitalization of $214.32 million and generates $3.89 million in revenue each year. The biotechnology company earns $-44,350,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. Aeglea Bio Therapeutics employs 61 workers across the globe.View Additional Information About Aeglea Bio Therapeutics.

The official website for Aeglea Bio Therapeutics is http://www.aegleabio.com/.

Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]